Chimeric antigen receptor T cells are one of the newest immunotherapy options for multiple myeloma treatment.
Their novelty and effectiveness led to a surge in demand among a patient subgroup in dire need of new therapies for relapsed or refractory disease, leading to widespread manufacturing and administration delays that slowed access to CAR-T.
This resulted in greater need for bridging therapy to prevent patients from developing uncontrollable disease or tumor-related organ dysfunction prior to CAR-T administration, according to Madhav V. Dhodapkar, MBBS, professor in the department of
